RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Trodelvy improved PFS by 34% in heavily pre-treated patients
I do believe that our results are good and that the market will wake up but trial design will be most important and it is good that onc will hopefully be proceeding with dual primary endpoints as pfs did not come through in indication 213 as per the press release.
Consistent with REOLYSIN® acting as an immune therapy agent, there was no meaningful improvement in either progression free survival (the primary endpoint), or response rate (secondary endpoint). With this overall survival data and the additional data from the p53 patient group, the company has commenced the planning of a registration study in metastatic breast cancer with overall survival as the primary endpoint.
So it would appear initially that pela and pfs will only be consistent depending upon how patients were previously treated and the kol panel was noting similar. I do like the duel endpoints as from what we know, os will be winning out on this as we still do not os for the bracelet results and suggestions that results will not be until 2024 definitly work in our favor although I do hope that onc and possible partners do not wait that long to do a deal. For sure it feels like our time is indeed getting closer.